9 0 6 7 6
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 2.6 Breast Cancer (Dove Med Press)
- 3.9 Clin Epidemiol
- 3.3 Cancer Manag Res
- 3.9 Infect Drug Resist
- 3.6 Clin Interv Aging
- 4.8 Drug Des Dev Ther
- 2.8 Int J Chronic Obstr
- 8.0 Int J Nanomed
- 2.3 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 4.0 OncoTargets Ther
- 2.2 Patient Prefer Adher
- 2.8 Ther Clin Risk Manag
- 2.7 J Pain Res
- 3.3 Diabet Metab Synd Ob
- 4.3 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.9 Pharmgenomics Pers Med
- 3.5 Risk Manag Healthc Policy
- 4.5 J Inflamm Res
- 2.3 Int J Gen Med
- 4.1 J Hepatocell Carcinoma
- 3.2 J Asthma Allergy
- 2.3 Clin Cosmet Investig Dermatol
- 3.3 J Multidiscip Healthc
已发表论文
Fascin-1 表达对非小细胞肺癌 (NSCLC) 患者的临床病理意义
Authors Ling XL, Zhang T, Hou XM, Zhao D
Published Date June 2015 Volume 2015:8 Pages 1589—1595
DOI http://dx.doi.org/10.2147/OTT.S84308
Received 10 March 2015, Accepted 24 April 2015, Published 30 June 2015
Approved for publication by Dr Faris Farassati
Purpose: Fascin-1 promotes the formation of filopodia, lamellipodia, and microspikes of cell membrane after its cross-linking with F-actin, thereby enhancing the cell movement and metastasis and invasion of tumor cells. This study explored the fascin-1 protein’s expression in non-small cell lung cancer (NSCLC) tissues and its relationship with clinical pathology and prognostic indicators.
Methods: Immunohistochemical analysis was used to determine the expression of fascin-1 in NSCLC tissues. We used quantitative real-time polymerase chain reaction and western blot analysis to further verify the results. The fascin-1 expression and statistical method for clinical pathological parameters are examined by χ 2. Kaplan–Meier method is used for survival analysis. Cox’s Proportional Hazard Model was used to conduct a combined-effect analysis for each covariate.
Results: In 73 of the 128 cases, NSCLC cancer tissues (57.0%) were found with high expression of fascin-1, which was significantly higher than the adjacent tissues (35/128, 27.3%). The results suggested that the high expression of fascin-1 was significantly correlated with lymph node metastasis (P =0.022) and TNM stage (P =0.042). The high fascin-1 expression patients survived shorter than those NSCLC patients with low fascin-1 expression (P <0.05). Univariate analysis revealed that lymph node metastasis, TNM stage, and fascin-1 expression status were correlated with the overall survival. Similarly, lymph node metastasis, TNM stage, and fascin-1 expression status were significantly associated with the overall survival in multivariate analyses by using the Cox regression model.
Conclusion: The fascin-1 protein may be a useful prognostic indicator and hopeful new target for NSCLC patients.
Keywords: fascin-1, NSCLC, biomarker, prognosis
Methods: Immunohistochemical analysis was used to determine the expression of fascin-1 in NSCLC tissues. We used quantitative real-time polymerase chain reaction and western blot analysis to further verify the results. The fascin-1 expression and statistical method for clinical pathological parameters are examined by χ 2. Kaplan–Meier method is used for survival analysis. Cox’s Proportional Hazard Model was used to conduct a combined-effect analysis for each covariate.
Results: In 73 of the 128 cases, NSCLC cancer tissues (57.0%) were found with high expression of fascin-1, which was significantly higher than the adjacent tissues (35/128, 27.3%). The results suggested that the high expression of fascin-1 was significantly correlated with lymph node metastasis (P =0.022) and TNM stage (P =0.042). The high fascin-1 expression patients survived shorter than those NSCLC patients with low fascin-1 expression (P <0.05). Univariate analysis revealed that lymph node metastasis, TNM stage, and fascin-1 expression status were correlated with the overall survival. Similarly, lymph node metastasis, TNM stage, and fascin-1 expression status were significantly associated with the overall survival in multivariate analyses by using the Cox regression model.
Conclusion: The fascin-1 protein may be a useful prognostic indicator and hopeful new target for NSCLC patients.
Keywords: fascin-1, NSCLC, biomarker, prognosis
